crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
rosuvastatin "accord" 10 mg filmovertrukne tabletter
accord healthcare b.v. - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
rosuvastatin "accord" 20 mg filmovertrukne tabletter
accord healthcare b.v. - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
rosuvastatin "accord" 40 mg filmovertrukne tabletter
accord healthcare b.v. - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
rosuvastatin "glenmark" 10 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
rosuvastatin "glenmark" 20 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
rosuvastatin "glenmark" 40 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
rosuvastatin "teva" 10 mg filmovertrukne tabletter
teva b.v. - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
rosuvastatin "teva" 20 mg filmovertrukne tabletter
teva b.v. - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
rosuvastatin "teva" 40 mg filmovertrukne tabletter
teva b.v. - rosuvastatin calcium - filmovertrukne tabletter - 40 mg